VANCOUVER, British Columbia, July 12, 2005 (PRIMEZONE) -- Dr. John Todd, President and CEO of ProtoKinetix, Inc. (OTCBB:PKTX), reports today on the Company's progress towards the commercialization of the family of synthetic AFGPs (Antifreeze Glycoproteins). The results received today from ProteoCell Laboratory on low dosage testing of both monomeric and dimeric synthetic AFGP molecules on heart myoblast cells are very positive. The tests clearly indicate an increased survival of heart cells at all temperatures tested (from 22 degrees C to -3 degrees C) in the presence of AFGP. Eighty-five percent (85%) of the heart cells were proven to be viable after 16-hours at a temperature of -3 degrees C using only 1 mg. of AFGP per ml.
Based on this confirmation of efficacy, the Company believes that it can improve the survivability even further with increased concentrations of AFGP.
To date ProtoKinetix has:
1. acquired patented technology to synthesize the family of
AFGP molecules
2. conducted a research and development program to assess the
potential uses of AFGP molecules
3. proven stability of AFGP in hostile environments
4. provided independent (the National Institute of Chemistry in
France) confirmation of safety (lack of toxicity) on very
sensitive cells
5. developed three generations of synthetic AFGP molecules
which give PKTX the ability to produce a variety of
molecules tailored to meet specific needs
6. commissioned ProteoCell Biotechnologies to test efficacy
of synthetic AFGP's on various cells and blood products
7. commenced discussion with target specific institutions on
the commercialization of this family of AFGP molecules
About ProtoKinetix:
ProtoKinetix, Inc. is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President